Elysium has introduced Balance, a formulation combining its NAD+ precursor product Basis with S-equol and ergothioneine, positioned for perimenopausal and menopausal symptom relief alongside longer-term postmenopausal health. The company reports that an open-label pilot of Basis showed a significant increase in the estradiol-to-estrone ratio with reductions in hot flashes, disrupted sleep and bloating; a larger randomized placebo-controlled trial is planned. The estradiol-to-estrone ratio is an emerging marker of reproductive aging, making it a measurable target rather than a symptom-only endpoint.
Key Points
- Basis pilot reported higher estradiol-to-estrone ratio in menopausal women
- S-equol and ergothioneine added for hot flashes, bone, sleep
- Evidence remains open-label; randomized placebo-controlled trial planned
Longevity Analysis
The menopausal transition compresses several aging trajectories at once — bone density, vascular tone, sleep architecture, thermoregulation and metabolic flexibility all shift within a narrow window. Targeting the estradiol-to-estrone ratio reframes intervention around a quantifiable hormonal signal rather than symptom suppression alone, which allows response to be tracked over time instead of inferred. Cellular energy metabolism, antioxidant capacity and estrogen receptor signaling are addressed as a single interconnected problem here, though the supporting data is early and uncontrolled, and the planned randomized trial will determine whether the mechanistic logic holds.
Original published by LT Wire.